FIG. 1A



MATCH WITH FIG. 1B

MATCH WITH FIG. 1A

FIG. 1B



MATCH WITH FIG. 1C

MATCH WITH FIG. 1B

FIG. 1C

```
     TTTACAGACAAGTTCATTCCATTATTAGACGTTCCCTGCCAGCAACACTACCACAGTGTC
661  ---------+---------+---------+---------+---------+---------+ 720
     AAATGTCTGTTCAAGTAAGGTAATAATCTGCAAGGGACGGTCGTTGTGATGGTGTCACAG
C      Y  R  Q  V  H  S  I  I  R  R  S  L  P  A  T  L  P  Q  C  Q -

     AGGCAGCGAACAAGACCTGCCCCACCAATTACATGTGGAATAATCACATCTGCAGATGCC
721  ---------+---------+---------+---------+---------+---------+ 780
     TCCGTCGCTTGTTCTGGACGGGGTGGTTAATGTACACCTTATTAGTGTAGACGTCTACGG
C      A  A  N  K  T  C  P  T  N  Y  M  W  N  N  H  I  C  R  C  L -

     TGGCTCAGGAAGATTTTATGTTTTCCTCGGATGCTGGAGATGACTCAACAGATGGATTCC
781  ---------+---------+---------+---------+---------+---------+ 840
     ACCGAGTCCTTCTAAAATACAAAAGGAGCCTACGACCTCTACTGAGTTGTCTACCTAAGG
C      A  Q  E  D  F  M  F  S  S  D  A  G  D  D  S  T  D  G  F  H -

     ATGACATCTGTGGACCAAACAAGGAGCTGGATGAAGAGACCTGTCAGTGTGTCTGCAGAG
841  ---------+---------+---------+---------+---------+---------+ 900
     TACTGTAGACACCTGGTTTGTTCCTCGACCTACTTCTCTGGACAGTCACACAGACGTCTC
C      D  I  C  G  P  N  K  E  L  D  E  E  T  C  Q  C  V  C  R  A -

     CGGGGCTTCGGCCTGCCAGCTGTGGACCCCACAAAGAACTAGACAGAAACTCATGCCAGT
901  ---------+---------+---------+---------+---------+---------+ 960
     GCCCCGAAGCCGGACGGTCGACACCTGGGGTGTTTCTTGATCTGTCTTTGAGTACGGTCA
C      G  L  R  P  A  S  C  G  P  H  K  E  L  D  R  N  S  C  Q  C -

     GTGTCTGTAAAAACAAACTCTTCCCCAGCCAATGTGGGGCCAACCGAGAATTTGATGAAA
961  ---------+---------+---------+---------+---------+---------+ 1020
     CACAGACATTTTTGTTTGAGAAGGGGTCGGTTACACCCCGGTTGGCTCTTAAACTACTTT
```

MATCH WITH FIG. 1D

MATCH WITH FIG. 1C

FIG. 1D



MATCH WITH FIG. 1E

MATCH WITH FIG. 1D

FIG. 1E



FIG. 2A

FIG.2B

FIG. 2C



FIG. 2D



FIG. 3A

```
        201                                                        250
Pdgfa   ....TSLNPD YREEDTDVR. .......... .......... ..........
Pdgfb   RSPGGSQEQR AKTPQTRVTI RTVRVRRPPK GKHRKFKHTH DKTALKETLG
 Vegf   RGK....... .GKGQKRKRK KSRYKSWSVY VGARCCLMPW SLPGPHP...
Vegf2   RRSLPATLPQ CQAANKTCPT NYMWNNHICR CLAQEDFMFS SDAGDDSTDG

        251                                                        300
Pdgfa   .......... .......... .......... .......... ..........
Pdgfb   A......... .......... .......... .......... ..........
 Vegf   ....CGP... .......... .......CSE RRKHLFVQDP QTCKCSCKNT
Vegf2   FHDICGPNKE LDEETCQCVC RAGLRPASCG PHKEL...DR NSCQCVCKNK

        301                                                        350
Pdgfa   .......... .......... .......... .......... ..........
Pdgfb   .......... .......... .......... .......... ..........
 Vegf   ..DSRCKARQ LELNERTCRC DKPRR..... .......... ..........
Vegf2   LFPSQCGANR .EFDENTCQC VCKRTCPRNQ PLNPGKCACE CTESPQKCLL

        351                                                        398
Pdgfa   .......... .......... .......... .......... ........
Pdgfb   .......... .......... .......... .......... ........
 Vegf   .......... .......... .......... .......... ........
Vegf2   KGKKFHHQTC SCYRRPCTNR QKACEPGFSY SEEVCRCVPS YWQRPQMS
```

FIG. 3B

PERCENTAGE (%) OF AMINO ACID IDENTITIES BETWEEN EACH PAIR OF GENES IS SHOWN IN THE FOLLWING TABLE				
	PDGF α	PDGF β	VEGF	VEGF2
PDGF α				
PDGF β	48.0			
VEGF	20.7	22.7		
VEGF2	23.5	22.4	30.0	

FIG. 4

Expression of VEGF2 mRNA in Human Breast Tumor Cells



1. normal breast tissue
2. breast tumor tissue
3-9. breast tumor cell lines.

FIG. 5



1. ovary
2. testes
3. gall bladder
4. kidney
5. liver
6. lung
7. spleen
8. prostate
9. Hippocampus
10. heart

Expression of VEGF2 mRNA in human adult tissues.

FIG. 6

FIG. 7



Lane 1: 14-C and rainbow M.W. marker
Lane 2: FGF control
Lane 3: VEGF2 (M13-reverse & forward primers)
Lane 4: VEGF2 (M13-reverse & VEGF-F4 primers)
Lane 5: VEGF2 (M13-reverse & VEGF-F5 primers)

non-reducing gel



Lane M: Marker
Lane 1: vector medium
Lane 2: VEGF2 medium

FIG. 8A

reducing gel



Lane M: Marker
Lane 1: vector cytoplasm
Lane 2: vector medium
Lane 3: VEGF2 cytoplasm
Lane 4: VEGF2 medium

FIG. 8B

FIG. 9



Lane 1: Molelular weight marker
Lane 2. Precipitates containing VEGF2.

FIG. 10



FIG. 11


Red
Green
Blue
Absorbance at 215 na
Absorbance at 280 na
0.6000
0.4000
0.2000
0.000
0.1000
0.0500
0.0000
0.00
5.00
10.00
13.21

FIG. 12



FIG. 13